Relaxation of rat thoracic aorta by fibrate drugs correlates with their potency to disturb intracellular calcium of VSMCs

Vascular Pharmacology

Volumn 56, Issue 3-4, 2012, Pages 168-175

  Liu, Aiming ^a   Yang, Julin ^b   Huang, Xiaoli ^c   Xiong, Jingfang ^c   Wong, Ada Hang Heng ^d   Chang, Lan ^a   Dai, Renke ^c  

^a NINGBO UNIVERSITY   (China)

^b Ningbo College of Health Sciences   (China)

^c SOUTH CHINA UNIVERSITY OF TECHNOLOGY   (China)

^d TSINGHUA UNIVERSITY   (China)

Author keywords

Fibrates; Intracellular calcium; Relaxation; Thoracic aorta; VSMCs

Indexed keywords

BEZAFIBRATE; CALCIUM ION; FENOFIBRIC ACID; GEMFIBROZIL;

ANIMAL CELL; ANIMAL TISSUE; ARTERY DILATATION; ARTICLE; CALCIUM CELL LEVEL; CARDIOVASCULAR EFFECT; CONCENTRATION RESPONSE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DRUG POTENCY; FLOW CYTOMETRY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER; SMOOTH MUSCLE TONE; THORACIC AORTA; VASCULAR SMOOTH MUSCLE CELL;

ANIMALS; AORTA, THORACIC; ATHEROSCLEROSIS; BEZAFIBRATE; CALCIUM SIGNALING; CELLS, CULTURED; FENOFIBRATE; FLOW CYTOMETRY; GEMFIBROZIL; HYPOLIPIDEMIC AGENTS; KINETICS; MALE; MICROSCOPY, CONFOCAL; MUSCLE, SMOOTH, VASCULAR; OSMOLAR CONCENTRATION; RATS; RATS, SPRAGUE-DAWLEY; VASODILATION; VASODILATOR AGENTS;

EID: 84862809430     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2012.01.003     Document Type: Article

References (36)

1. Abshagen U., Sporl-Radun S., Marinow J. Steady-state kinetics of bezafibrate and clofibrate in healthy female volunteers. Eur. J. Clin. Pharmacol. 1980, 17:305-308.
2. Arakawa E., Hasegawa K. Benidipine, a calcium channel blocker, regulates proliferation and phenotype of vascular smooth muscle cells. J. Pharmacol. Sci. 2006, 100:149-156.
3. Backman J.T., Kyrklund C., Neuvonen M., Neuvonen P.J. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin. Pharmacol. Ther. 2002, 72:685-691.
4. Borghi C., Dormi A., Veronesi M., Sangiorgi Z., Gaddi A. Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study. Am. Heart J. 2004, 148:285-292.
5. Calkin A.C., Cooper M.E., Jandeleit-Dahm K.A., Allen T.J. Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation. Diabetologia 2006, 49:766-774.
6. Dzau V.J., Braun-Dullaeus R.C., Sedding D.G. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat. Med. 2002, 8:1249-1256.
7. eNigro J., Ballinger M.L., Dilley R.J., Jennings G.L., Wight T.N., Little P.J. Fenofibrate modifies human vascular smooth muscle proteoglycans and reduces lipoprotein binding. Diabetologia 2004, 47:2105-2113.
8. Fairhurst A.S., Kent G., Purdy R.E. Clofibrate and vascular smooth muscle: actions on rabbit aorta preparations. Eur. J. Pharmacol. 1981, 72:323-329.
9. Fisher T.E., Levy S., Kaczmarek L.K. Transient changes in intracellular calcium associated with a prolonged increase in excitability in neurons of Aplysia californica. J. Neurophysiol. 1994, 71:1254-1257.
10. Graham D.J., Staffa J.A., Shatin D., Andrade S.E., Schech S.D., La Grenade L., Gurwitz J.H., Chan K.A., Goodman M.J., Platt R. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004, 292:2585-2590.
11. Gustavson L.E., Schweitzer S.M., Burt D.A., Achari R., Rieser M.J., Edeki T., Chira T., Yannicelli H.D., Kelly M.T. Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, three-period crossover study in healthy subjects. Clin. Ther. 2006, 28:373-387.
12. Hartigan J.A., Johnson G.V. Transient increases in intracellular calcium result in prolonged site-selective increases in Tau phosphorylation through a glycogen synthase kinase 3beta-dependent pathway. J. Biol. Chem. 1999, 274:21395-21401.
13. Hodel C. Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol. Lett. 2002, 128:159-168.
14. Hollenbeck S.T., Nelson P.R., Yamamura S., Faries P.L., Liu B., Kent K.C. Intracellular calcium transients are necessary for platelet-derived growth factor but not extracellular matrix protein-induced vascular smooth muscle cell migration. J. Vasc. Surg. 2004, 40:351-358.
15. Kim J.I., Tsujino T., Fujioka Y., Saito K., Yokoyama M. Bezafibrate improves hypertension and insulin sensitivity in humans. Hypertens. Res. 2003, 26:307-313.
16. Kip S.N., Hunter L.W., Ren Q., Harris P.C., Somlo S., Torres V.E., Sieck G.C., Qian Q. [Ca2+]i reduction increases cellular proliferation and apoptosis in vascular smooth muscle cells: relevance to the ADPKD phenotype. Circ. Res. 2005, 96:873-880.
17. Kyrklund C., Backman J.T., Neuvonen M., Neuvonen P.J. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin. Pharmacol. Ther. 2003, 73:538-544.
18. Laufs U. Beyond lipid-lowering: effects of statins on endothelial nitric oxide. Eur. J. Clin. Pharmacol. 2003, 58:719-731.
19. Lee J.J., Jin Y.R., Yu J.Y., Munkhtsetseg T., Park E.S., Lim Y., Kim T.J., Pyo M.Y., Hong J.T., Yoo H.S., Kim Y., Yun Y.P. Antithrombotic and antiplatelet activities of fenofibrate, a lipid-lowering drug. Atherosclerosis 2009, 206:375-382.
20. Liu A., Xie S., Sun H., Gonzalez F.J., Wei X., Dai R. Myotoxicity of gemfibrozil in cynomolgus monkey model and its relationship to pharmacokinetic properties. Toxicol. Appl. Pharmacol. 2009, 235:287-295.
21. Liu A., Yang J., Gonzalez F.J., Cheng G.Q., Dai R. Biphasic regulation of intracellular calcium by gemfibrozil contributes to inhibiting L6 myoblast differentiation: implications for clinical myotoxicity. Chem. Res. Toxicol. 2011, 24:229-237.
22. Mattson M.P., Chan S.L. Calcium orchestrates apoptosis. Nat. Cell Biol. 2003, 5:1041-1043.
23. Nigro J., Dilley R.J., Little P.J. Differential effects of gemfibrozil on migration, proliferation and proteoglycan production in human vascular smooth muscle cells. Atherosclerosis 2002, 162:119-129.
24. Ogilvie B.W., Zhang D., Li W., Rodrigues A.D., Gipson A.E., Holsapple J., Toren P., Parkinson A. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab. Dispos. 2006, 34:191-197.
25. Peters J.M., Cheung C., Gonzalez F.J. Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand?. J. Mol. Med. 2005, 83:774-785.
26. Phelps L.E., Peuler J.D. Evidence of direct smooth muscle relaxant effects of the fibrate gemfibrozil. J. Smooth Muscle Res. 2010, 46:125-142.
27. Phillips J.E., Preston Mason R. Inhibition of oxidized LDL aggregation with the calcium channel blocker amlodipine: role of electrostatic interactions. Atherosclerosis 2003, 168:239-244.
28. Rubins H.B., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam M.B., Faas F.H., Linares E., Schaefer E.J., Schectman G., Wilt T.J., Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. 1999, 341:410-418.
29. Schachter M. Vascular smooth muscle cell migration, atherosclerosis, and calcium channel blockers. Int. J. Cardiol. 1997, 62(Suppl 2):S85-S90.
30. Schneck D.W., Birmingham B.K., Zalikowski J.A., Mitchell P.D., Wang Y., Martin P.D., Lasseter K.C., Brown C.D., Windass A.S., Raza A. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin. Pharmacol. Ther. 2004, 75:455-463.
31. Shitara Y., Hirano M., Sato H., Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J. Pharmacol. Exp. Ther. 2004, 311:228-236.
32. Song Q.B., Wei M.J., Duan Z.Q., Zhang H.Q., Schwartz L.B., Xin S.J. Batroxobin reduces intracellular calcium concentration and inhibits proliferation of vascular smooth muscle cells. Chin. Med. J. (Engl) 2004, 117:917-921.
33. Staffa J.A., Chang J., Green L. Cerivastatin and reports of fatal rhabdomyolysis. N. Engl. J. Med. 2002, 346:539-540.
34. Takemoto M., Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler. Thromb. Vasc. Biol. 2001, 21:1712-1719.
35. Williams J.M., Zhao X., Wang M.H., Imig J.D., Pollock D.M. Peroxisome proliferator-activated receptor-alpha activation reduces salt-dependent hypertension during chronic endothelin B receptor blockade. Hypertension 2005, 46:366-371.
36. Zanetti M., Stocca A., Dapas B., Farra R., Uxa L., Bosutti A., Barazzoni R., Bossi F., Giansante C., Tedesco F., Cattin L., Guarnieri G., Grassi G. Inhibitory effects of fenofibrate on apoptosis and cell proliferation in human endothelial cells in high glucose. J. Mol. Med. 2008, 86:185-195.